Local News

• Dyax and AVEO Pharmaceuticals announce antibody library license agreement  Dyax and AVEO Pharmaceuticals announced that Dyax has granted AVEO a non-exclusive license to Dyax's proprietary antibody phage display libraries for the discovery and development of therapeutic antibodies.
  Dyax Corp. July 22, 2008  
• Forest Laboratories reports fiscal first quarter 2009 earnings per share of $0.79  Forest Laboratories announced that fully diluted earnings per share equaled $0.79 in the first quarter of fiscal 2009. Reported earnings per share include a one-time pre- tax charge of $44,100,000, or $0.08 per share net of tax.
  Forest Laboratories, Inc. July 22, 2008  
• Cynosure receives CE Mark for Smartlipo MPX(TM) workstation  Cynosure has received the European CE Mark for Smartlipo MPX(TM), the company's high-powered, dual-wavelength aesthetic workstation to liquefy fat and tighten skin through collagen remodeling.
  Cynosure, Inc. July 22, 2008  
• Critical Therapeutics files Registration Statement on Form S-4 with SEC  Critical Therapeutics announced that it has filed a Registration Statement on Form S-4 with the Securities and Exchange Commission containing the preliminary Proxy Statement/Prospectus in connection with the announced merger agreement between Critical Therapeutics and Cornerstone BioPharma.
  Critical Therapeutics, Inc. July 22, 2008  
• Hoping two drugs carry a side effect: longer life  One day last month, clad in white plastic garments from head to toe, Dr. David Sinclair showed a visitor around his germ-free mouse room at Harvard Medical School. The mice, subjects in studies of health and longevity, are kept in wire baskets under intensive nursing care.
  The New York Times July 22, 2008  Nicholas Wade
• Merck announces fourth quarter 2008 dividend  The Board of Directors of Merck & Co. declared a quarterly dividend of $0.38 per share on the Company's common stock for the fourth quarter of 2008.
  Merck & Co., Inc. July 22, 2008  
• Curis selects Hsp90 inhibitor CUDC-305 as development candidate  Curis announced that the Company has selected an orally available, synthetic small molecule inhibitor of heat shock protein 90 (Hsp90) as a development candidate from its targeted cancer drug development platform.
  Curis, Inc. July 21, 2008  
• Alnylam grants new InterfeRx(TM) intellectual property license to Calando  Alnylam Pharmaceuticals announced that it has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, a new target-specific InterfeRx(TM) license to discover, develop, and commercialize a synthetic siRNA directed toward an undisclosed cancer gene target.
  Alnylam Pharmaceuticals, Inc. July 21, 2008  
• Senate Appropriations Committee approves $2 billion for FDA  The Senate Appropriations Committee unanimously passed an appropriations markup measure Thursday, providing the FDA with a $2.04 billion fiscal 2009 budget. This amount is $324.6 million more than the agency initially received for fiscal 2008.
  FDAnews July 21, 2008  
• Wyeth Pearl River Facility earns OSHA VPP Star; 2,000th workplace recognized in U.S.  Wyeth announced that its manufacturing and research facility in Pearl River, N.Y., has earned the highest recognition for workplace safety and health from the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA): the Voluntary Protection Programs (VPP) "star."
  Wyeth July 21, 2008  

   (next 10 articles)